EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
These filings come after FDA issued its latest warning to patients and healthcare professionals about the serious dangers of compounded GLP-1 drugs
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
The survey revealed that the proportion of individuals experiencing constant thoughts about food throughout the day declined by 46 percent after starting Wegovy
The study showed a significant 29% reduction in the risk for heart attack, stroke and death from any cause in the Wegovy users
The accelerated approval is supported by results from part 1 of the ESSENCE trial
The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants
The submission is based on data from the STEP UP and STEP UP T2D clinical trials
Subscribe To Our Newsletter & Stay Updated
